Physician
Debarros, Claudio
Debarros, Claudio was paid $742K by Medicaid between Jan 2018 and Mar 2023, across 28 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 38% of everything it billed.
33Billing provider infoDEBARROS, CLAUDIO
BOSTON, MA 02111
BOSTON, MA 02111
33aNPI1114213105assigned 06/28/2011
33bProvider typePediatrics Physician
28Total paid$742K
24GClaims20,296
24DCodes billed28
24AFirst – last monthJan 2018 – Mar 2023
Compared with peers
Next to other Pediatrics Physician providers in Massachusetts
Rank by total paid#102 of 1,273
Median peer was paid$24K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,603 | $128K | |
| 2019 | 4,261 | $144K | |
| 2020 | 3,236 | $116K | |
| 2021 | 3,089 | $112K | |
| 2022 | 5,039 | $199K | |
| 2023 | 1,068 | $42K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 38% | 4,788 | 4,279 | $285K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 13% | 2,920 | 2,285 | $99K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9.2% | 810 | 810 | $68K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.8% | 500 | 479 | $50K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.8% | 520 | 520 | $43K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.2% | 389 | 375 | $31K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 3.6% | 2,955 | 2,944 | $27K |
| 90461 | 3.5% | 719 | 716 | $26K | |
| 99173 | 3.4% | 1,119 | 1,119 | $25K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.4% | 197 | 196 | $18K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.3% | 1,647 | 1,646 | $17K |
| 96127 | 1.6% | 1,162 | 1,160 | $12K |
16 more codes
| 99177 | 1.5% | 753 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 506 | $7K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 142 | $3K |
| 99051 | <1% | 189 | $3K | |
| 0071A | <1% | 65 | $3K | |
| 0072A | <1% | 53 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 152 | $2K |
| 92551 | <1% | 202 | $2K | |
| 99050 | <1% | 27 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 81 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 37 | $770.85 |
| 87430 | <1% | 21 | $483.00 | |
| 94760 | <1% | 98 | $450.80 | |
| 87081 | <1% | 64 | $437.76 | |
| 85018 | <1% | 167 | $374.44 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13 | $153.79 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.